Skip to main content

Table 1 Clinico-pathological characteristics of patients

From: miRNA signature associated with outcome of gastric cancer patients following chemotherapy

  Gastric cancer patient Healthy volunteer
  Training
set
Proof-of-principle
test set
(responder)
 
Number 82 8 34
Age - yr    
   Median 56 56 48
   Interquartile range (44-63) (44-58) (43-57)
Sex - no. (%)    
   Male 64 (78.0%) 7 (87.5%) 23 (67.6%)
   Female 18 (22.0%) 1 (12.5%) 11 (32.4%)
Performance status (PS) - no. (%)    
   ECOG1 PS 0 or 1 73 (89.0%) 8 (100%)  
   ECOG PS 2 or 3 9 (11.0%) 0  
Histological type - no. (%)    
   Lauren's intestinal 34 (41.5%) 3 (37.5%)  
   Lauren's diffuse 48 (58.5%) 5 (62.5%)  
Location of primary lesion - no. (%)    
   Upper 1/3 11 (13.4%) 1 (12.5%)  
   Middle 1/3 18 (22.0%) 5 (62.5%)  
   Lower 1/3 43 (52.4%) 1 (12.5%)  
   Entire stomach 10 (12.2%) 1 (12.5%)  
Chemotherapy regimen - no. (%)    
   Cisplatin/Fluorouracil 80 (97.6%) 8 (100%)  
   Cisplatin/Capecitabine 2 (2.4%) 0  
*Relative dose intensity - %    
   Median 81.2 76.6  
   Interquartile range (75.3-87.3) (64.7-84.9)  
Number of chemotherapy cycles    
   Median 4 10  
   Interquartile range (2-5) (7-11)  
Chemotherapy response (WHO criteria) -no (%)    
   PR2 16 (24.6%) 6 (100%)  
   SD3 25 (38.5%)   
   PD4 24 (36.9%)   
   Unmeasurable 16 2  
   Unevaluable 1   
Second-line chemotherapy 55 (67.1%) 6 (75.0%)  
Median follow-up for survivors 35.5 months -  
Overall survival - mo.    
   Median 8.2 16  
   Interquartile range (6.8-10.5) (11.3-26.7)  
Time to progression - mo .    
   Median 3.1 8.2  
   Interquartile range (2.5-3.9) (4.3-21.2)  
  1. 1Eastern Cooperative Oncology Group, 2partial response, 3stable disease, 4progressive disease
  2. *Relative dose intensity
  3. *Mean of relative dose intensities of cisplatin and fluorouracil. Dose intensity is defined as the amount of drug administered per unit of time, expressed as milligrams per square meter per week. Relative dose intensity is defined as the actual dose intensity relative to the planned dose intensity of each drug.